Tesamorelin: The Only Approved GHRH Analogue on This Axis

Tesamorelin is human growth hormone-releasing hormone in its full-length 44-residue form, GHRH(1-44), carrying one chemical addition: a trans-3-hexenoyl group attached at the N-terminal tyrosine. PubChem resolves it as CID 16137828, formula C221H366N72O67S, molecular weight 5135.9 g/mol, CAS 218949-48-5. In the older literature it appears under its development code, TH9507.

The hexenoyl group exists for one reason, and it is enzymatic. Native GHRH is cleaved by dipeptidyl peptidase-4 between the second and third residues. That single cut removes the N-terminal dipeptide the GHRH receptor depends on for activation, and it happens fast enough that endogenous GHRH has a circulating half-life measured in minutes. Occupying the N-terminus with a bulky acyl group sterically obstructs the enzyme's access to that bond.

This puts tesamorelin in the same structural family as sermorelin and both CJC-1295 variants: GHRH-receptor agonists engineered around the same vulnerability. The differences are in scope and strategy. Tesamorelin keeps the whole 44-residue sequence and protects it with an acyl cap. Modified GRF (1-29) - the compound sold as CJC-1295 without DAC - works from the truncated 1-29 fragment and substitutes four residues instead. CJC-1295 with DAC takes that same fragment and bolts on an albumin-binding linker. Ipamorelin does not belong to this family at all; it engages GHS-R1a, the ghrelin receptor, on an entirely separate pathway.

Tesamorelin binds the GHRH receptor, a class B G-protein-coupled receptor expressed on pituitary somatotrophs. Engagement raises intracellular cAMP through Gs, which drives synthesis and release of stored growth hormone. Growth hormone then acts on the liver and other tissues, and hepatic IGF-1 output rises as a downstream consequence. IGF-1 is therefore the pharmacodynamic marker followed in the trials - it is the readable signal that the receptor was engaged.

The architecturally important point is where in the axis this happens. Tesamorelin acts one step upstream of the pituitary, so the pituitary remains the thing that actually decides how much growth hormone is released, and it remains under the opposing influence of somatostatin and under negative feedback from IGF-1. Growth hormone secretion therefore stays episodic. Administering growth hormone itself bypasses all of that regulation and produces a concentration profile determined by the administered material rather than by the hypothalamus.

Whether that distinction translates into a different biological result is a genuinely open question rather than a settled advantage, and the CJC-1295 literature is where it gets tested most directly - Ionescu and Frohman showed that pulsatility survives even continuous GHRH-receptor stimulation, while Vance and colleagues produced conflicting findings on somatotroph desensitisation during sustained GHRH exposure. Tesamorelin's contribution to that debate is indirect: its trials measured clinical endpoints, not secretion architecture.

This is where tesamorelin separates from everything else on the axis. Falutz and colleagues published a pooled analysis of two multicentre, double-blind, placebo-controlled Phase 3 trials, each with a randomised phase followed by a safety extension, in people living with HIV who had excess abdominal fat. Both trials reported reductions in visceral adipose tissue relative to placebo, with IGF-1 rising as expected. The FDA approved the compound in 2010 for HIV-associated lipodystrophy.

It is worth stating plainly what that means in comparison. CJC-1295 with DAC has one published human study of any size. Modified GRF (1-29) has essentially none under that name. Ipamorelin has a single Phase 2 proof-of-concept trial in an unrelated indication. Tesamorelin has two completed Phase 3 programmes, a regulatory review, and a label with defined monitoring requirements. These are not comparable evidential positions, and grouping the four compounds together as interchangeable 'growth hormone peptides' hides a difference of several orders of magnitude in scrutiny.

The 2026 meta-analysis by Badran and colleagues pools the randomised trials quantitatively across body-composition, hepatic and metabolic endpoints. Its value is partly in the aggregation and partly in what the inclusion table reveals: fifteen years on, the controlled evidence base still consists of trials in one clinical population. The review by Spooner and Olin covers the same material from the monitoring side, including the glucose and IGF-1 signals that shaped the approved label.

In 2019 Stanley and colleagues published a randomised, double-blind, multicentre trial in the Lancet HIV examining tesamorelin in HIV-associated non-alcoholic fatty liver disease. They reported reduced liver fat relative to placebo. This work matters for reasons beyond the result: it was independent NIH-supported research rather than sponsor-run registration work, and it moved the question from a body-composition measure to an organ-specific one.

A companion literature grew around it. Related analyses examined hepatic transcriptomic signatures and circulating markers of immune activation in the same trial population, which is unusual depth for any compound in this catalogue and reflects academic rather than commercial interest.

The boundary on all of this is the enrolled population. Every pivotal and follow-on trial studied people living with HIV, most on antiretroviral therapy, with a specific pattern of fat redistribution and metabolic disturbance. That is a population with an identified physiological problem the GHRH axis plausibly addresses. Whether the same intervention produces the same measurements in metabolically healthy adults has not been established by trials of this quality, and the literature does not license the inference.

Population is the first limit, and it is the one most often ignored. The second is metabolic: growth hormone opposes insulin action, and increases in fasting glucose have been a recurring monitoring point across the trial literature and the approved label. This is a characterised property of the pharmacology rather than an unexplained adverse signal, but it means the compound's metabolic effect is not uniformly favourable across measures.

Durability is the third. The reported effects on visceral adipose tissue in the Phase 3 programme were not maintained after the intervention stopped, which the trial extensions were designed to examine. Any framing that presents the effect as a structural change rather than a maintained pharmacological state misreads the data.

Finally, an approved pharmaceutical and a laboratory reference material are different objects even when the sequence matches. The Phase 3 dataset attaches to a specific manufactured product, its formulation, and its label conditions. Material characterised on a lot certificate of analysis for in vitro work carries none of that, and the trial results above should not be read across to it.